Last reviewed 2026-04-20 · How we verify

Proendotel (CLORICROMEN)

Phase 2 active Small molecule

Proendotel (generic name: CLORICROMEN) is a cloricromen drug. It is currently in Phase 2 development for Thromboembolic disorder.

Cloricromen works by inhibiting platelet aggregation, which is the process by which platelets clump together to form blood clots.

Proendotel, also known as Cloricromen, is a small molecule drug in the cloricromen class. It is used to treat thromboembolic disorders, although its exact target is unknown. The commercial status of Proendotel is unclear, and it is not known whether it is patented or available as a generic. Further information on its pharmacokinetics, such as half-life and bioavailability, is also lacking. As a result, key safety considerations and potential side effects are not well established.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CLORICROMEN
Drug class	cloricromen
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 2

Mechanism of action

Imagine your blood as a liquid with tiny particles called platelets that help it clot when you're injured. Cloricromen stops these platelets from sticking together as much, which can help prevent blood clots from forming and reduce the risk of thromboembolic disorders.

Approved indications

Thromboembolic disorder

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Proendotel CI brief — competitive landscape report
Proendotel updates RSS · CI watch RSS

Frequently asked questions about Proendotel

What is Proendotel?

Proendotel (CLORICROMEN) is a cloricromen drug, indicated for Thromboembolic disorder.

How does Proendotel work?

Cloricromen works by inhibiting platelet aggregation, which is the process by which platelets clump together to form blood clots.

What is Proendotel used for?

Proendotel is indicated for Thromboembolic disorder.

What is the generic name of Proendotel?

CLORICROMEN is the generic (nonproprietary) name of Proendotel.

What drug class is Proendotel in?

Proendotel belongs to the cloricromen class. See all cloricromen drugs at /class/cloricromen.

What development phase is Proendotel in?

Proendotel is in Phase 2.

Drug class: All cloricromen drugs
Therapeutic area: All drugs in Cardiovascular
Indication: Drugs for Thromboembolic disorder

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing